Lipoxin receptor agonist, may be a potential treatment for hemorrhagic shock-induced acute lung injury

Medical Hypotheses

Volumn 79, Issue 1, 2012, Pages 92-94

  Gong, Jie ^a   Li, Hong Bin ^a   Guo, Si ^a   Shang, You ^a   Yao, Shang Long ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BML 111; CYTOKINE; CYTOKINE RECEPTOR AGONIST; LIPOXIN RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HEMORRHAGIC SHOCK; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; RAT;

ACUTE LUNG INJURY; ANIMALS; RATS; RECEPTORS, LIPOXIN; SHOCK, HEMORRHAGIC;

EID: 84861454638     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.04.010     Document Type: Article

References (26)

1. Dong W., Cai B., Peña G., et al. Ethyl pyruvate prevents inflammatory responses and organ damage during resuscitation in porcine hemorrhage. Shock 2010, 34(2):205-213.
2. Kauvar D.S., Lefering R., Wade C.E. Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations. J Trauma 2006, 60:S3-S11.
3. Keel M., Trentz O. Pathophysiology of polytrauma. Injury 2005, 36:691-709.
4. Yang C.H., Tsai P.S., Wang T.Y., et al. Dexmedetomidine-ketamine combination mitigates acute lung injury in haemorrhagic shock rats. Resuscitaion 2009, 80:1204-1210.
5. Maderna P., Godson C. Lipoxins: resolutionary road. Br J Pharmacol 2009, 158(4):947-959.
6. Clish C.B., O'Brien J.A., Gronert K., Stahl G.L., Petasis N.A., Serhan C.N. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc Natl Acad Sci USA 1999, 96:8247-8252.
7. Bannenberg G., Moussignac R.L., Gronert K., et al. Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration. Br J Pharmacol 2004, 143:43-52.
8. Wu Y., Wang Y.P., Guo P., et al. A lipoxin A(4) analog ameliorates blood-brain barrier dysfunction and reduces MMP-9 expression in a rat model of focal cerebral ischemia-reperfusion injury. J Mol Neurosci 2011, [Epub ahead of print].
9. Forsman H., Dahlgren C. Lipoxin A(4) metabolites/analogues from two commercial sources have no effects on TNF-α-mediated priming or activation through the neutrophil formyl peptide receptors. Scand J Immunol 2009, 70:396-402.
10. 4 receptor agonist, on carbon tetrachloride-induced liver injury in mice. Hepatol Res 2007, 37:948-956.
11. Conte F.P., Menezes-de-Lima O., Verri W.A., Cunha F.Q., Penido C., Henriques M.G. Lipoxin A(4) attenuates zymosan-induced arthritis by modulating endothelin-1 and its effects. Br J Pharmacol 2010, 161:911-924.
12. Al Amran F.G., Hadi N.R., Hashim A.M. Leukotriene biosynthesis inhibition ameliorates acute lung injury following hemorrhagic shock in rats. J Cardiothorac Surg 2011, 6:81. PMID: 21649921.
13. Shang Y., Jiang Y.X., Xu S.P., et al. Reduction of pulmonary inflammatory response by erythropoietin in a rat model of endotoxaemia. Chin Med J 2009, 122:834-838.
14. Wu Y., Ye X.H., Guo P.P., et al. Neuroprotective effect of lipoxin A4 methyl ester in a rat model of permanent focal cerebral ischemia. J Mol Neurosci 2010, 42:226-234.
15. Wang Y.P., Wu Y., Li L.Y., et al. Aspirin-triggered lipoxin A4 attenuates LPS-induced pro-inflammatory responses by inhibiting activation of NF-κB and MAPKs in BV-2 microglial cells. J Neuroinflamm 2011, 8:95. PMID: 21831303.
16. Abraham E. Neutrophils and acute lung injury. Crit Care Med 2003, 31:S195-S199.
17. Olanders K., Sun Z., Borjesson A., et al. The effect of intestinal ischemia and reperfusion injury on ICAM-1 expression, endothelial barrier function, neutrophil tissue influx, and protease inhibitor levels in rats. Shock 2002, 18:86-92.
18. Zemans R.L., Colgan S.P., Downey G.P. Transepithelial migration of neutrophils mechanisms and implications for acute lung injury. Am J Respir Cell Mol Biol 2009, 40:519-535.
19. Decker Y., Mcbean G., Godson C. Lipoxin A4 inhibits IL-1beta-induced IL-8 and ICAM-1 expression in 1321N1 human astrocytoma cells. Am J Physiol Cell Physiol 2009, 296(6):C1420-C1427.
20. Matsuo Y., Onodera H., Shiga Y., et al. Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat: effects of neutrophil depletion. Stroke 1994, 25:1469-1475.
21. Nauseef W.M. How human neutrophils kill and degrade microbes: an integrated view. Immunol Rev 2007, 219:88-102.
22. Chiang N., Serhan C.N., Dahlen S.-E., et al. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev 2006, 58:463-487.
23. Lawrence T., Gilroy D.W., Colville-Nash P.R., Willoughby D.A. Possible new role for NF-kappaB in the resolution of inflammation. Nat Med 2001, 7:1291-1297.
24. Sha W.C. Regulation of immune responses by NF-κB/Rel transcription factor. J Exp Med 1998, 187:143-146.
25. Sun T., Yu E., Yu L., Luo J., Li H., Fu Z. LipoxinA(4) induced antinociception and decreased expression of NF-κB and pro-inflammatory cytokines after chronic dorsal root ganglia compression in rats. Eur J Pain 2011, [Epub ahead of print].
26. Ye X.H., Wu Y., Guo P.P., et al. Lipoxin A4 analogue protects brain and reduces inflammation in a rat model of focal cerebral ischemia reperfusion. Brain Res 2010, 1323:174-183.